Latest / ESWI Airborne's Podcast / From Spillover to the Brain: Understanding Zoonotic Viruses Across the Life Cycle of Infection
Transcript
- 0:00Aida Bakri: Welcome to ESWI Airborne.
- 0:02Aida Bakri: In this series featuring our early career scientist community, we explore how the next generation is shaping the future of respiratory virus research.
- 0:10Aida Bakri: This series is made possible thanks to the kind support of CSL Seqirus and Sanofi Pasteur.
- 0:39Jane Barratt: I'm Jane Barrett, and it is a pleasure to host today's conversation.
- 0:44Jane Barratt: As part of our early career scientists series, today we'll be talking to two researchers working at different points along the same continuum of risk.
- 0:55Jane Barratt: They're going to explore why zoonotic viruses remain central to global health security and why preparedness requires both early detection and a deep understanding of what happens once a virus enters the human body.
- 1:11Jane Barratt: Today's session follows that arc from environmental surveillance to neurological consequence and asks what true preparedness demands.
- 1:23Jane Barratt: Let me introduce our speakers for today.
- 1:26Jane Barratt: The first, Dr.
- 1:28Jane Barratt: Nico Halwe.
- 1:29Jane Barratt: Nico is a virologist working at the intersection of urban ecology and pandemic preparedness.
- 1:36Jane Barratt: He's based in Vienna and studies viruses circulating in urban wildlife, particularly rodents and birds that live alongside us in cities.
- 1:47Jane Barratt: Using advanced genomic sequencing and citizen science approaches, he detects both known and previously undiscovered viruses before they emerge as public health threats.
- 2:00Jane Barratt: His focus is early warning.
- 2:03Jane Barratt: By mapping how newly identified viruses relate to known high-risk pathogens, he assesses their zoonotic potential and supports more informed risk evaluation before these outbreaks occur.
- 2:20Jane Barratt: So we welcome Nico to our conversation today.
- 2:24Jane Barratt: Next, I'd like to introduce Dr.
- 2:28Jane Barratt: Lisa Bauer.
- 2:29Jane Barratt: Lisa is a neuroscientist and virologist who studies how viruses invade and damage the brain.
- 2:37Jane Barratt: Her research examines pathogens such as avian influenza and SARS-CoV-2, focusing on how they infect different brain cell types and trigger neurological disease.
- 2:51Jane Barratt: Her work centers on consequence.
- 2:54Jane Barratt: She investigates why some viral strains cause severe neurological complications while closely related strains do not, and whether damage is driven primarily by the virus or the immune response.
- 3:10Jane Barratt: So welcome to you both, Nico and Lisa.
- 3:13Jane Barratt: How are you today?
- 3:16Nico Joel Halwe: Thanks for having us.
- 3:17Nico Joel Halwe: So I'm I'm very excited to be here.
- 3:20Nico Joel Halwe: And thanks for the invitation.
- 3:22Lisa Bauer: Good.
- 3:22Lisa Bauer: And Lisa?
- 3:23Lisa Bauer: Yeah, thanks.
- 3:24Lisa Bauer: I think it's really cool.
- 3:25Lisa Bauer: And I mean, today I'm sitting in Rotterdam, so today we have 17 degrees in sunshine, so it couldn't be a better weather, actually.
- 3:32Jane Barratt: Well, it's it it sounds like it's perfect weather.
- 3:35Jane Barratt: Um, so welcome to you both.
- 3:37Jane Barratt: Nico, I really want to start talking with you about this urban interface and you know, with the focus on early warning and surveillance science.
- 3:48Jane Barratt: So the first thing that we need to know really is when you're sampling urban wildlife, what are you actually finding?
- 3:55Jane Barratt: Are most viruses benign or are there consistent signals that we need to be concerned about?
- 4:02Nico Joel Halwe: That's actually a very good question because, and and I have to say, actually, I cannot answer that yet right now because the past month it was actually pretty busy, or we were pretty busy with setting up a lab in Vienna from scratch, so we had no infrastructure at all.
- 4:19Nico Joel Halwe: And we are currently at a stage where we are finally able to dissect uh rodents from the urban wildlife and see what's in there.
- 4:28Nico Joel Halwe: So so far we haven't we haven't been able to start yet, but the first rodents that we uh and samples that we get are coming at the end of this week, and then um we can we can find out and we investigate more.
- 4:40Nico Joel Halwe: But of course, we have we have some ideas um of what we what we can expect.
- 4:44Nico Joel Halwe: So there were a lot of um cases with influenza viruses, of course, in in the past in wildlife detected, but also Pumala Auto Hunter virus was a major cause of infection in in rodents, but also human cases in the past.
- 5:00Nico Joel Halwe: So we expect these viruses to be present also in in the urban wildlife that we are sampling, but we also of course want to know which which kind of viruses are new and which which have not been found before.
- 5:13Nico Joel Halwe: So this is what we what we are going to do.
- 5:16Jane Barratt: Yeah, well, congratulations on setting up your your lab.
- 5:19Jane Barratt: That's uh that's a great step forward.
- 5:21Jane Barratt: You know, in your experience though, you know, could you give us a sort of flavor of whether most viruses are benign or are there consistent signals or don't we know that yet?
- 5:36Nico Joel Halwe: Well, it's a difficult question, actually.
- 5:38Nico Joel Halwe: I think we still have to find out, especially in Austria.
- 5:41Nico Joel Halwe: So um, yeah, we really have to, I think we just have to start and and see what we find and what we what we can expect.
- 5:50Jane Barratt: Look, thank you for that.
- 5:51Jane Barratt: So we're really waiting on the precipice for this.
- 5:54Jane Barratt: But Lisa, you've been studying, you know, neuro invasion and clinical consequences for quite some time.
- 6:01Jane Barratt: So could you explain to us when a virus invades the central nervous system, what determines whether disease is going to be mild or severe?
- 6:13Lisa Bauer: Yeah, so there's actually multiple factors.
- 6:16Lisa Bauer: And I think uh the the first, we really have to look at the word invade.
- 6:20Lisa Bauer: So, what does this actually mean?
- 6:21Lisa Bauer: And with neuroinvasion, we actually mean that the virus can enter the brain through cranial nerves or peripheral nerves, or it can also happen through the blood.
- 6:32Lisa Bauer: And that determines, for example, if you have a respiratory virus or a gastrointestinal virus, how it can enter the brain.
- 6:38Lisa Bauer: And I think it's very nice to, or it's it's good to see on the example of SARS-CoV-2 and influenza viruses, because they do replicate in our nose.
- 6:49Lisa Bauer: And within our nose, for example, we have two different types of sites where they replicate.
- 6:54Lisa Bauer: One we call the olfactory mucosa.
- 6:57Lisa Bauer: And this is very interesting because there we have neurons that protrude into our nasal cavity and actually sample the environment.
- 7:06Lisa Bauer: And if a virus can infect that, and this has been shown, that SARS-CoV-2 and influenza viruses replicate the two quite high titers, they have a shortcut to the brain.
- 7:16Lisa Bauer: So that's actually quite concerning if we see that a virus has a preference for the olfactory pathway.
- 7:25Lisa Bauer: However, we also have other viruses, as for example, I think a beautiful example is poliovirus that can uh enter the spinal cord, so um through motor neurons, and actually through the spinal cord travel up into a brain.
- 7:41Lisa Bauer: So you already see that in these cases it is not so easy to actually determine whether this leads to a mild or severe disease.
- 7:54Jane Barratt: You know, that's really fascinating.
- 7:56Jane Barratt: You know, you talked about you know cranial, peripheral, and then blood.
- 8:02Jane Barratt: So there are different pathways.
- 8:03Jane Barratt: And and you know, the word fast track really took my attention.
- 8:08Jane Barratt: You know, the the olfactory pathway is a fast track.
- 8:12Jane Barratt: Um so you know, when in in practical terms, you know, what's the message for people in the general community when it comes to you know viruses?
- 8:26Lisa Bauer: Yeah, I I I think the message is that it can depend on the way the virus enters the brain, whether it has consequ whether it has more severe consequences or not.
- 8:38Lisa Bauer: However, the whether a virus invades the brain alone is not sufficient to tell us that.
- 8:44Lisa Bauer: So we actually need to understand more.
- 8:47Lisa Bauer: But the neurovision is just the first step.
- 8:50Jane Barratt: Oh my goodness, it's that's fascinating.
- 8:52Jane Barratt: Look, I'll come back to you, Lisa, and and ask you another another question on that.
- 8:57Jane Barratt: But it it Nico, I'm I'm coming back to you again in terms of you know the zoonotic potential of previously unknown viruses.
- 9:09Jane Barratt: Um now, your work really looks at genomic sequencing.
- 9:14Jane Barratt: So, can you give us any indication of what the genomic or ecological characteristics, you know, red flags are when you're looking at um zoonotic potential?
- 9:26Nico Joel Halwe: Yeah, of course.
- 9:27Nico Joel Halwe: Um, so definitely genomic sequencing is basically the first step that we that we want to do.
- 9:32Nico Joel Halwe: And it's very important, and there are certain things that definitely from from scratch, and what when we see it, definitely uh we can we can already know that this might be something that could cause disease severity or um better transmission.
- 9:48Nico Joel Halwe: For example, with um SARS-CoV-2, we had this polybasic cleavage site.
- 9:53Nico Joel Halwe: This is also something that uh, or polybasic cleavage site is also happening and occurring in in H5 and 1, uh, avian influenza.
- 10:03Nico Joel Halwe: So um, these are certain indications that already suggest that this might be a virus that um is capable of doing um yeah bad things in in vitro and in vivo.
- 10:15Nico Joel Halwe: But uh we're not just looking at genomic sequences, so we really want to want to have this approach of virus discovery as first step to really identify new viruses and then go a step further and really um yeah, isolate these viruses or generate these viruses by reverse genetics and in then in-depth uh characterize these viruses in vitro and in vivo to really get an idea of um how um yeah of the zoolontic potential because it's it's necessary to just uh characterize these viruses and not just detect it to get an idea of how dangerous these really are.
- 10:56Jane Barratt: You know, you you mentioned this this term of discovering viruses.
- 11:00Jane Barratt: You know, if I think about the current surveillance systems, what are the major blind spots in our current systems, particularly in cities?
- 11:11Jane Barratt: Because, you know, your work has a tremendous public health um implications, you know, from the from the position of identifying viruses and then ensuring that we have the right public health messages.
- 11:27Jane Barratt: So what are the major blind spots in the current systems of surveillance?
- 11:33Nico Joel Halwe: I think I think what is primarily neglected often is really the city itself, because uh most most surveillance efforts really focus on like more rural areas in, for example, jungle with exotic species, to see which kind of viruses are circulating there.
- 11:50Nico Joel Halwe: But really, efforts to detect viruses in in urban environments is is kind of something that is neglected most of the time.
- 11:59Nico Joel Halwe: And that's where we exactly want to step in because um there are often situations where people in the city itself um are coming in contact with animals sometimes also without even knowing.
- 12:13Nico Joel Halwe: So with bird droppings on a park bench or like I don't know, a rodent running around in a garage where you just uh sweep the floor afterwards.
- 12:24Nico Joel Halwe: Uh there are uh studies with bornavirus infections uh that may be happening uh based on these kinds of incidents.
- 12:33Nico Joel Halwe: Uh so a lot of things inside the city itself are not really uh considered.
- 12:39Nico Joel Halwe: And uh yeah, we want to find out where are the threats there and and how can we address this by by knowing which or shedding more light on what is circulating in the city in the in the wildlife.
- 12:53Jane Barratt: We certainly don't um we we don't have readily available public health information on what you're talking about, you know, bird droppings or rodents.
- 13:05Jane Barratt: You know, I think of when where I live in Toronto, you know, raccoons, um, you know, you know, skunks, um, you know, they are in downtown downtown Toronto.
- 13:18Jane Barratt: Um, and I'm wondering why we don't have this public health information readily available.
- 13:26Jane Barratt: Lisa, what are your thoughts about that in terms of public health information?
- 13:30Jane Barratt: Do you know why we don't have it up front?
- 13:34Lisa Bauer: Yeah, it's uh I think that's a very good question.
- 13:37Lisa Bauer: And it's also difficult to answer.
- 13:41Lisa Bauer: So I think one of the things is for sure cost, and you need dedicated people to do that, which is not always uh that easy because surveillance, uh, it is more I would say it's more on an expensive side.
- 13:57Lisa Bauer: Uh, we also see it with, for example, with the surveillance of highly pathogenic even influenza viruses, that we have a very suboptimal uh surveillance system, and in the end we focus on regions where you do see disease upcoming, right?
- 14:13Lisa Bauer: Um, so I think we do miss a lot.
- 14:16Lisa Bauer: Um so I think it's really great to have this uh way to look at uh especially urbanization, um, to understand what is out there and what can be a danger to public health.
- 14:31Jane Barratt: And that's why you know you as early career scientists are so important because you you know you're at the front line of this research.
- 14:40Jane Barratt: So I think it's very important.
- 14:42Jane Barratt: I I want to talk with you a little bit more, Lisa, about you know, how do strain differences influence neurovirulence?
- 14:52Lisa Bauer: Yeah.
- 14:53Lisa Bauer: So I mean, as as uh I think as uh Nico already uh mentioned before, for example, for transmission, you have this poorly basic cleavage site of SARS-CoV-2 that uh showed that uh SARS-CoV-2 was uh more readily airborne transmissible.
- 15:08Lisa Bauer: So also viral factors can actually play a role in understanding whether different strains can cause uh or influence the neovirulence, so to say.
- 15:21Lisa Bauer: And for example, maybe let's take uh let's say with influenza viruses.
- 15:24Lisa Bauer: So we know quite well that uh you have seasonal and influenza viruses, that's these viruses that circulate yearly in the human population, and they also do cause some uh neurological uh complications, but relatively modest.
- 15:41Lisa Bauer: However, if you, for example, look at the highly pathogenic even influenza virus, one of the hallmarks of these differences between these two viruses is that highly pathogenic even influenza viruses have a multibasic leavage site.
- 15:53Lisa Bauer: And we do see that this is, for example, very important to allow these viruses to replicate in neurons.
- 16:01Lisa Bauer: I mean, this is just one point.
- 16:02Lisa Bauer: We also know that uh other gene segments are drivers of an enhanced uh neurovirulence.
- 16:10Lisa Bauer: So with neurovirulence, maybe that's also good to actually define this word.
- 16:14Lisa Bauer: What I mean with this is actually the ability of a virus infection to cause damage to the CNS, right?
- 16:21Lisa Bauer: Um, and this can be the virus can either uh enter the brain, but it must not always enter the brain, right?
- 16:30Lisa Bauer: So you you can have neurovirulence from the virus that goes into your brain, but also from virus, for example, from excessive uh inflammation in the primary replication site.
- 16:40Lisa Bauer: And there are also, for example, some differences between seasonal influenza viruses and highly pathogenic avenue influenza viruses.
- 16:46Lisa Bauer: So you you have different drivers and yeah, receptors can play a difference as we have uh shown with different SARS-CoV-2 variants.
- 16:55Lisa Bauer: So it's certainly important, is uh it is not one sole factor that determines what is the difference in the neovirulent potential between different virus strains.
- 17:08Jane Barratt: And and I suppose that someone that has a number of chronic comorbidities, such as diabetes, you know, COPD, um, then they would be at higher risk, you know, uh in in terms of um you know the neuro invasion.
- 17:28Lisa Bauer: Yes, uh that's uh that's certainly, but that's more on the on the host side, yes.
- 17:33Lisa Bauer: So of course receptive expressions, uh promorbidities.
- 17:37Jane Barratt: Uh so uh Nico, I'm I'm interested, you know, what your day-to-day work looks like, and I'm going to ask you too, Lisa, you know, it because what you've talked about is highly sophisticated, you know, scientific research, you know, but you're also talking about areas that impact each and every one of us in the general population.
- 18:05Jane Barratt: So, Nico, when your lab is up and running, you know, what are you doing in terms of you know the frontline work?
- 18:15Nico Joel Halwe: Um, yeah, so um basically uh what we've what we've started right now, uh we're trying to get this public also with my mentor Florian Kramer, um, who um we want to uh reach out to citizens, citizen science project, which is called we named it ViroKitty.
- 18:33Nico Joel Halwe: So basically we engage with uh um with with citizens from Vienna that they notify us when uh their cat brought home a rodent, for example, or a small bird, so that they contact us and we will uh uh pick them up from their home, basically, take it to the lab, dissect it, and then do our uh surveillance and uh virus discovery approaches to hopefully see and detect new viruses and then uh down um downstream basically also do what I what I've just mentioned with um virus isolation attempts and characterization of these viruses in vitro and in vivo.
- 19:13Nico Joel Halwe: So we really want to want to involve the the citizens uh directly in the science part.
- 19:18Nico Joel Halwe: We want to also get back to them when we have results to tell them what we found out so that we have yeah, so that we get a little bit more trust uh from the citizens, uh which was especially since the COVID-19 pandemic is very, very important, uh I would say.
- 19:36Jane Barratt: You know, you know, you're you're really engaging with the general public, and that's part of public health education, isn't it?
- 19:43Jane Barratt: So as well as the scientific research, you're really educating the general public uh as well.
- 19:49Jane Barratt: So just just remind the audience once again, what's the title of of this campaign?
- 19:57Nico Joel Halwe: Uh the the project that's started is ViroKitty.
- 20:00Nico Joel Halwe: You can you can find it online on our website from the LBI soap.
- 20:05Nico Joel Halwe: It's basically called ViroKitty.
- 20:08Jane Barratt: Okay.
- 20:08Jane Barratt: So what we'll do is we'll make sure that we have that uh that that link because I think it's very important, not only in your country, but you know, around the world, the audience actually has access to to what's what's happening.
- 20:24Jane Barratt: So I'll go back to Lisa and I'm fascinated.
- 20:29Jane Barratt: I want to know, is neurological damage primarily driven by the virus itself or by the host immune response?
- 20:37Jane Barratt: Or is it I know what you're gonna say, Lisa.
- 20:40Jane Barratt: You're gonna say, well, this is complicated.
- 20:43Jane Barratt: So tell us, you know, give us your give us your give us your best version of what we could expect.
- 20:51Lisa Bauer: It is both.
- 20:52Lisa Bauer: I think the the answer is quite easy in this case.
- 20:55Lisa Bauer: It is both.
- 20:56Lisa Bauer: And I mean, first, it really depends whether the virus can replicate in neurons or not, or in other cell types of the CNS.
- 21:06Lisa Bauer: Because I think if the virus productively replicates, like for example, uh highly pathogenic uh H5N1 virus, it very fast spreads uh through the whole brain, and this fast spread causes a massive inflammation within the brain and just a shutdown of the whole brain function.
- 21:23Lisa Bauer: I think what is more interesting is for example SARS-CoV-2 or seasonal influenza viruses, because there what you see is a little bit something different.
- 21:33Lisa Bauer: It's a hit and run model.
- 21:35Lisa Bauer: So the virus enters the brain but is restricted in the growth, so it cannot spread throughout the brain.
- 21:42Lisa Bauer: And then the host, of course, tries to get rid of this infection, um, which at some point the host detects, of course, this one or two uh infected uh neurons and tries to get rid of them.
- 21:57Lisa Bauer: And at the moment, what we Do see is that you actually often what often results, especially if we think of long COVID, that you have a hyperactivation of the immune system, and then you also produce auto antibodies that that uh can exacerbate uh the disease, for example, auto antibodies against interferon, it's uh uh a molecule that antagonizes uh viruses or other uh cell types.
- 22:23Lisa Bauer: So, but yeah, it's it's it's certainly both.
- 22:25Lisa Bauer: So in on the other hand, it can also be driven mostly by the host.
- 22:32Lisa Bauer: So, for what I mean by that, if we if we now think of a virus that doesn't enter the central nervous system, what can happen?
- 22:40Lisa Bauer: So the virus replicates in our lungs, we have an excessive inflammation, and through the blood, at some point the blood will cross uh in into close proximity to the brain.
- 22:52Lisa Bauer: And what these cytokins and anti uh inflammatory responses can do, they actually can weaken the blood-brain barrier to easily allow the uptake uh of compounds, toxic compounds or viruses.
- 23:07Lisa Bauer: So, as I said, it really can be both.
- 23:11Jane Barratt: You know, we've heard from Nico that um you know there's probably a lack of awareness, you know, around the potential impact of zoonotic viruses, you know, in in um in cities.
- 23:23Jane Barratt: When we come to learn about the impact of avian influenza and SARS-CoV-2, are the neurological risks being underestimated in the community and public health in general?
- 23:39Lisa Bauer: Yes.
- 23:39Lisa Bauer: That uh is for sure.
- 23:42Lisa Bauer: I mean, I I I think that also So I think the problem actually starts that we do not really know the frequency of how often these viruses enter the CNS.
- 23:51Lisa Bauer: Right?
- 23:52Lisa Bauer: I mean, in if you go, for example, if you take cats as sentinel, they often uh eat dead carcasses, so the viruses replicates in the olfactory mucosa, easily spreads to the brain very fast, uh, very, very fast, and causes often uh death uh because of these neurological symptoms, and a lot of other animals also develop neurological symptoms.
- 24:16Lisa Bauer: So I think it is there, but I'm I'm actually not really sure why this is not comprehensive also in the human population, that you can get this neurological uh understanding because we always often what you actually see is that if if the virus has a has a certain reservoir and it causes, for example, their neurological complications, if it spills over to a new reservoir, you often see that actually the symptoms are very similar at the size of the replication.
- 24:48Lisa Bauer: So I'm actually not really sure why often neurological complications are, I would rather say overlooked, not rather underestimated.
- 24:57Jane Barratt: No, they're they're certainly, certainly overlooked, as are, you know, zoonotic, the potential of zoonotic viruses.
- 25:04Jane Barratt: I just want to ask both of you just one really important question, because I often talk about the importance of cross-sector and cross-discipline cooperation and partnerships.
- 25:15Jane Barratt: So if there was one interface that you could strengthen between your disciplines, what would it be?
- 25:22Jane Barratt: Perhaps if we start with you, Lisa, and then we'll go to Nico.
- 25:27Lisa Bauer: I think what would be really interesting would be a genotype to phenotype classification.
- 25:33Lisa Bauer: So you actually understand the genome of these viruses and you kind of can hypothesize whether that would lead to neurological uh symptoms or not.
- 25:42Lisa Bauer: And I think that's really uh something uh what we need to work on, especially for pandemic preparedness.
- 25:49Nico Joel Halwe: Definitely.
- 25:49Nico Joel Halwe: I I I couldn't I couldn't agree more.
- 25:52Nico Joel Halwe: So that's that's definitely the the way to go.
- 25:54Nico Joel Halwe: So detecting new things, the first thing that you have is a sequence, and then from there on you have to see what can it do and and um how dangerous could it be.
- 26:05Nico Joel Halwe: So basically, really characterization is I think a topic that we both uh are interested in and which is very important.
- 26:12Nico Joel Halwe: And this of course uh yeah includes the neuroinvasion because it's often it is like if it invades the the CNS, then we have a very severe disease.
- 26:23Nico Joel Halwe: So um it's very important to really characterize new uh viruses when we discover them.
- 26:31Jane Barratt: Oh, look, thank you.
- 26:32Jane Barratt: Um as we're coming to the end of the podcast, I want to come back to both of you and ask you what is your takeaway message for the audience that's listening to this fascinating conversation?
- 26:45Jane Barratt: So, Nico, what do you want, you know, the um the audience to to take away from you know what you've talked about today?
- 26:56Nico Joel Halwe: Yeah, basically, so this is maybe basically uh one one uh thing that I already touched upon on.
- 27:02Nico Joel Halwe: Uh so people I think often forget that zoonotic viruses are not only circulating in in the exotic environments, so just in jungles or in in in uh fruitbed colonies in Africa or in in several animal species in China, but it can be also in Germany, in Austria, in the Netherlands, wherever you are.
- 27:21Nico Joel Halwe: Um so it can be right outside uh your apartment.
- 27:25Nico Joel Halwe: And I think it's important to just be aware of the environment, uh, take it carefully, and it's also I think a good idea to wash your hands now and then.
- 27:35Jane Barratt: You know I I think that's really good basic public health, but you know, raising the awareness of just be conscious of your environment and the consequences of infections, you know, outside your apartment and perhaps even inside your apartment.
- 27:53Jane Barratt: So, Lisa, what's your takeaway message?
- 27:58Lisa Bauer: My takeaway message is that uh a lot of different viruses, even though the respirator the replicate maybe in the gastrointestinal tract and the respiratory tract can actually spread to extra respiratory tissue, especially also uh to the brain, and that this is often underestimated.
- 28:16Lisa Bauer: And I think the SARS-CoV-2 pandemic, especially with association of long COVID, really highlighted this because I mean, especially long COVID, this is not something new.
- 28:26Lisa Bauer: This post-acute sequela, we already know since the Spanish uh flu pandemic in 1918, or uh polio with post-polio uh encephalitis, or um with measles long-term neurological complications.
- 28:43Lisa Bauer: So this is really not a new concept, but I think maybe it is really time to finally take it serious and to actually understand what do these viruses, if they enter the brain, what do they do in the short term, and what will be the consequences on the long term?
- 28:58Lisa Bauer: Can they lead to neurodenugeneration?
- 29:00Lisa Bauer: And how actually can we fight that?
- 29:03Lisa Bauer: And I think that will be uh very important in the future to understand.
- 29:08Jane Barratt: Two very clear closing messages.
- 29:12Jane Barratt: So today's discussion reminds us that zoonotic risk follows a continuum, it begins in the environments which we share with wildlife, and that doesn't mean in the jungles, as as Nico said, it's it's outside your apartment, or it could be inside.
- 29:29Jane Barratt: You know, it's in your local environment and can extend deep into the human body through various ways, as Lisa said.
- 29:37Jane Barratt: You know, cranial, peripheral, blood.
- 29:40Jane Barratt: Preparedness is not a single action.
- 29:44Jane Barratt: It depends on early detection and on a deep understanding of the biological consequence.
- 29:50Jane Barratt: So without surveillance, we are surprised.
- 29:53Jane Barratt: Without mechanistic insight, we underestimate risk.
- 29:58Jane Barratt: And both Nico and Lisa have been very clear about currently we underestimate risk.
- 30:06Jane Barratt: And Lisa made a very good point just now about this is not new.
- 30:11Jane Barratt: We need to start taking it seriously.
- 30:13Jane Barratt: True preparedness connects these stages before crisis forces them together.
- 30:20Jane Barratt: Um, I've had a great time talking with you both, Nico and Lisa, and thank you to our audience for joining as we airborne.
- 30:28Jane Barratt: And Lisa and Nico, I wish you great success in the future.
- 30:32Jane Barratt: We need you at the front line, and we also need your messages in public health interventions going forward.
- 30:40Jane Barratt: So thank you very much for your dedication and your commitment.
- 30:44Jane Barratt: Thank you.
- 30:45Nico Joel Halwe: Thank you so much.
- 30:46Nico Joel Halwe: Yeah, thanks for the invitation.
- 30:53Aida Bakri: ESWI Airborne is brought to you by ESWI, the European Scientific Working Group on Influenza and other acute respiratory viruses.
- 31:01Aida Bakri: These episodes would not be possible without the team's efforts, and I would like to extend special thanks to our ESWI Secretariat, our technical and IT teams, our arts team, and our host.
- 31:12Aida Bakri: The podcasts are recorded virtually, and we thank our guests for their participation in this inspiring and educational series.
- 31:21Aida Bakri: Talks are adapted to a global audience and are intended as recommendations and guiding principles.
- 31:28Aida Bakri: For any specific medical questions you may have, these should be addressed to your local general practitioner.
- 31:34Aida Bakri: Many thanks to our sponsoring partners, and thank you for listening.